Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities

Yun Chung Leung; Alisa Sau Wun Shum

Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities

Yun Chung Leung (Inventor)
, Alisa Sau Wun Shum (Inventor)

Research output: Patents, agreements, assignments and companies › Patents granted

Abstract

The present disclosure relates to arginase albumin binding domain (ABD) fusion proteins and methods of preparation and use thereof. Also provided are methods involving arginine depletion for the treatment of obesity, metabolic disorders, and related complications and comorbidities.

Original language	English
Patent number	EP3802621
Filing date	31/05/19
Publication status	Published - 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{9688efe79a7d44b4b912e533d1059ca4,

title = "Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities",

abstract = "The present disclosure relates to arginase albumin binding domain (ABD) fusion proteins and methods of preparation and use thereof. Also provided are methods involving arginine depletion for the treatment of obesity, metabolic disorders, and related complications and comorbidities. ",

author = "Leung, \{Yun Chung\} and Shum, \{Alisa Sau Wun\}",

year = "2026",

language = "English",

type = "Patent",

note = "EP3802621",

}

TY - PAT

T1 - Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities

AU - Leung, Yun Chung

AU - Shum, Alisa Sau Wun

PY - 2026

Y1 - 2026

N2 - The present disclosure relates to arginase albumin binding domain (ABD) fusion proteins and methods of preparation and use thereof. Also provided are methods involving arginine depletion for the treatment of obesity, metabolic disorders, and related complications and comorbidities.

AB - The present disclosure relates to arginase albumin binding domain (ABD) fusion proteins and methods of preparation and use thereof. Also provided are methods involving arginine depletion for the treatment of obesity, metabolic disorders, and related complications and comorbidities.

M3 - Patents granted

M1 - EP3802621

Y2 - 2019/05/31

ER -

Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities

Abstract

UN SDGs

Fingerprint

Cite this